LEVERKUSEN (dpa-AFX) - MorphoSys AG (MPSYY.PK) said that it earned a milestone payment with Bayer's initiation of a global phase 2 clinical study designed to support registration of anetumab ravtansine (BAY 94-9343).
Anetumab ravtansine, an antibody-drug conjugate or ADC targeting mesothelin, is a potential new treatment for mesothelioma developed by Bayer using MorphoSys's HuCAL technology. Further financial details were not disclosed.
MorphoSys's collaboration with Bayer has resulted in two clinical programs to date. In total, MorphoSys's partnered and proprietary clinical pipeline currently comprises 25 unique antibody molecules which are currently being evaluated in more than 50 clinical trials.
Copyright RTT News/dpa-AFX